User profiles for Marcus Maurer
 | Marcus MaurerProfessor, Institute of Allergology, Charité - Universitätsmedizin Berlin, Germany Verified email at charite.de Cited by 73742 |
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
This update and revision of the international guideline for urticaria was developed following
the methods recommended by Cochrane and the Grading of Recommendations Assessment…
the methods recommended by Cochrane and the Grading of Recommendations Assessment…
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
This evidence‐ and consensus‐based guideline was developed following the methods
recommended by Cochrane and the Grading of Recommendations Assessment, Development …
recommended by Cochrane and the Grading of Recommendations Assessment, Development …
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
Background Patients with chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU)
often continue to experience symptoms despite receiving standard-of-care therapy with H …
often continue to experience symptoms despite receiving standard-of-care therapy with H …
[HTML][HTML] Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria
Background Many patients with chronic idiopathic urticaria (also called chronic spontaneous
urticaria) do not have a response to therapy with H 1 -antihistamines, even at high doses. In …
urticaria) do not have a response to therapy with H 1 -antihistamines, even at high doses. In …
[HTML][HTML] The international WAO/EAACI guideline for the management of hereditary angioedema–the 2017 revision and update
Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate
therapy are essential. This update and revision of the global guideline for HAE provides …
therapy are essential. This update and revision of the global guideline for HAE provides …
Mast cells promote homeostasis by limiting endothelin-1-induced toxicity
Endothelin-1 (ET-1) is a 21-amino-acid peptide, derived from vascular endothelial cells,
with potent vasoconstrictor activity 1 . ET-1 has been implicated in diverse physiological or …
with potent vasoconstrictor activity 1 . ET-1 has been implicated in diverse physiological or …
[HTML][HTML] The international WAO/EAACI guideline for the management of hereditary angioedema–The 2021 revision and update
Hereditary Angioedema (HAE) is a rare and disabling disease for which early diagnosis and
effective therapy are critical. This revision and update of the global WAO/EAACI guideline …
effective therapy are critical. This revision and update of the global WAO/EAACI guideline …
Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase
M Maurer, S Altrichter, T Bieber, T Biedermann… - Journal of Allergy and …, 2011 - Elsevier
Background A subgroup of patients with chronic spontaneous urticaria (CU) exhibits IgE
antibodies directed against autoantigens, such as thyroperoxidase (TPO). We conducted this …
antibodies directed against autoantigens, such as thyroperoxidase (TPO). We conducted this …
[HTML][HTML] Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment
Background Attacks of hereditary angioedema (HAE) are unpredictable and, if affecting the
upper airway, can be lethal. Icatibant is used for physician- or patient self-administered …
upper airway, can be lethal. Icatibant is used for physician- or patient self-administered …
[HTML][HTML] Ligelizumab for chronic spontaneous urticaria
M Maurer, AM Giménez-Arnau… - … England Journal of …, 2019 - Mass Medical Soc
Background In the majority of patients with chronic spontaneous urticaria, most currently
available therapies do not result in complete symptom control. Ligelizumab is a next-generation …
available therapies do not result in complete symptom control. Ligelizumab is a next-generation …
